Organogenesis Holdings (ORGO)
NASDAQ:ORGO
Want to see ORGO full AI Analyst Report?
Top Page
Organogenesis Holdings
(NASDAQ:ORGO)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.50
▼(-38.73% Downside)
Action:ReiteratedDate:05/08/26
The score is weighed down primarily by weak cash conversion (negative operating/free cash flow) and a very challenging near-term outlook from the latest earnings call (sharp revenue declines and reduced 2026 guidance). Technicals also reflect a weak longer-term trend, while moderate leverage and liquidity (including no debt noted on the call) provide only partial support.
Positive Factors
Regulatory milestone (BLA)
Completing a BLA for ReNu is a durable strategic milestone that expands Organogenesis’ addressable market into non‑surgical knee OA. If approved, ReNu would create a new, higher‑margin revenue stream and diversify reliance on wound care product cycles over the medium term.
Negative Factors
Weak cash conversion
Negative operating and free cash flow in 2025 highlights poor cash conversion despite earnings rebound. Over the coming quarters this undermines self‑funding for working capital, commercialization and regulatory programs, increasing reliance on liquidity facilities or equity if losses persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory milestone (BLA)
Completing a BLA for ReNu is a durable strategic milestone that expands Organogenesis’ addressable market into non‑surgical knee OA. If approved, ReNu would create a new, higher‑margin revenue stream and diversify reliance on wound care product cycles over the medium term.
Read all positive factors
Organogenesis Holdings (ORGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$325.46M
Dividend YieldN/A
Average Volume (3M)1.62M
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue Growth17.04%
EPS Growth1511.69%
CountryUS
Employees869
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.12
Shares Outstanding128,640,670
10 Day Avg. Volume3,747,707
30 Day Avg. Volume1,624,131
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)1.16
P/FCF Ratio-26.84
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue0.50
Enterprise Value/Gross Profit0.68
Enterprise Value/Ebitda3.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$401.20M
Organogenesis Holdings Business Overview & Revenue Model
Company Description
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care product...
How the Company Makes Money
Organogenesis makes money primarily by selling its regenerative medicine products used in wound care and surgical applications. Revenue is generated when its products are purchased and used by healthcare providers (e.g., hospitals, outpatient faci...
Organogenesis Holdings Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Negative
The call detailed significant near-term financial deterioration driven by market disruption and policy-related clinician confusion: Q1 revenue fell 58% YoY, margins compressed sharply, and losses widened, prompting a material downgrade to full-year revenue guidance and a March restructuring. Offsetting these negatives are important strategic and clinical milestones — completion of a BLA submission for ReNu, a positive 170‑patient RCT for PuraPly AM, evidence of relative market share gains, disciplined cost reductions, and a solid cash position with no debt. While these highlights support longer-term confidence, they do not fully mitigate the severe short-term revenue and profitability declines and the uncertainty around CMS policy timing.Positive Updates
Completed BLA Submission for ReNu
On April 28 the company completed its BLA submission to the FDA for ReNu, a potential nonsurgical biologic for symptomatic knee osteoarthritis — a key regulatory milestone supporting future growth in a large unmet market.
Negative Updates
Severe Revenue Decline in Q1
Net product revenue for Q1 was $36.3M, down 58% year-over-year. Advanced Wound Care revenue declined 63% to $29.5M; Surgical & Sports Medicine revenue was $6.8M and flat year-over-year.
Read all updates
Q1-2026 Updates
Positive
Negative
Completed BLA Submission for ReNu
On April 28 the company completed its BLA submission to the FDA for ReNu, a potential nonsurgical biologic for symptomatic knee osteoarthritis — a key regulatory milestone supporting future growth in a large unmet market.
Read all positive updates
Company Guidance
Organogenesis updated 2026 net revenue guidance to $270 million–$310 million (a decline of ~45%–52% YoY vs prior guidance of a 25%–38% decline), now anticipating first‑half revenue declines of roughly 52%–49% YoY with sequential improvement thereafter and strong third‑ and fourth‑quarter growth but a more measured recovery overall; the company expects positive adjusted EBITDA generation in H2 and a return to more normalized profitability in Q4, plans to reduce operating expenses (ex‑COGS) ~25% YoY for 2026 (including >30% YoY in H2) and assumes ~$7 million of Q3–Q4 restructuring savings as part of an approximate $14 million annualized cost reduction from the March restructuring (88 employee reduction and St. Petersburg facility closure); these outlooks are framed against Q1 results of $36.3 million net product revenue (down 58% YoY), Advanced Wound Care $29.5M (down 63%), Surgical & Sports Medicine $6.8M (flat), an adjusted EBITDA loss of $48.2M, cash of $92.1M, no debt and $75M revolver availability, and reflect continued uncertainty from CMS commentary affecting utilization.Organogenesis Holdings Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
66
Positive
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 564.17M | 482.04M | 433.14M | 450.89M | 467.36M |
| Gross Profit | 415.06M | 366.30M | 326.66M | 345.87M | 353.16M |
| EBITDA | 83.32M | 15.76M | 36.03M | 40.32M | 87.00M |
| Net Income | 37.03M | 861.00K | 4.95M | 15.53M | 94.20M |
Balance Sheet | |||||
| Total Assets | 598.73M | 497.89M | 460.02M | 449.36M | 443.26M |
| Cash, Cash Equivalents and Short-Term Investments | 93.68M | 135.57M | 104.34M | 102.48M | 113.93M |
| Total Debt | 132.84M | 43.31M | 119.35M | 123.79M | 132.30M |
| Total Liabilities | 164.81M | 112.57M | 181.36M | 183.69M | 201.92M |
| Stockholders Equity | 433.92M | 385.32M | 278.66M | 265.67M | 241.34M |
Cash Flow | |||||
| Free Cash Flow | -24.46M | 4.18M | 6.55M | -9.04M | 30.76M |
| Operating Cash Flow | -10.31M | 14.21M | 30.92M | 24.86M | 61.98M |
| Investing Cash Flow | -14.15M | -10.03M | -24.36M | -33.90M | -31.22M |
| Financing Cash Flow | -17.36M | 27.64M | -5.50M | -2.20M | -1.04M |
Organogenesis Holdings Technical Analysis
Neutral
4.08
Price Trends
2.93
Negative
3.80
Negative
4.22
Negative
Market Momentum
-0.10
Negative
46.40
Neutral
77.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGO, the sentiment is Neutral. The current price of 4.08 is above the 20-day moving average (MA) of 2.39, above the 50-day MA of 2.93, and below the 200-day MA of 4.22, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 46.40 is Neutral, neither overbought nor oversold. The STOCH value of 77.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ORGO.
Organogenesis Holdings Risk Analysis
Organogenesis Holdings disclosed 73 risk factors in its most recent earnings report. Organogenesis Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Organogenesis Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $338.88M | ― | 11.26% | ― | -31.82% | -60.71% | |
61 Neutral | $471.07M | 15.84 | -1.59% | ― | -29.89% | 93.33% | |
56 Neutral | $420.81M | -6.28 | 174.92% | ― | 9.56% | 24.52% | |
54 Neutral | $375.84M | -12.05 | -1.00% | ― | 1.57% | 89.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $808.25M | 3.54 | 5.62% | ― | 21.31% | 27.38% | |
46 Neutral | $325.46M | -1.35 | 9.56% | ― | 17.04% | 1511.69% |
* Healthcare Sector Average
ORGO
Organogenesis Holdings
2.53
-0.53
-17.32%
EBS
Emergent Biosolutions
9.13
3.48
61.59%
SIGA
SIGA Technologies
4.73
-0.28
-5.51%
ESPR
Esperion
3.14
2.34
293.48%
EOLS
Evolus
6.39
-3.41
-34.80%
SNDL
SNDL
1.45
0.16
12.40%
Organogenesis Holdings Corporate Events
Executive/Board Changes
Organogenesis Names Patrick McGuire Chief Accounting Officer
Neutral
Feb 23, 2026
On February 18, 2026, Organogenesis Holdings Inc. appointed Patrick McGuire, 40, as Chief Accounting Officer and principal accounting officer, effective immediately, elevating him from his prior role as Vice President, Corporate Controller. McGuir...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.